DefinePK

Abstract

Background: Silver nanoparticles with inimitable physical, chemical, and biological characteristics have high antimicrobial capacity. Roflumilast, a PDE4 inhibitor, has now been investigated for anti-psoriatic efficacy as it reduces hyperproliferation and oxidative stress while improving the skin barrier. This study aimed to design Roflumilast-loaded silver nanoparticles (R-AgNPs) using Box Behnken Design (BBD) for optimization.
Materials and Methods: Silver nanoparticles (AgNPs) were formulated by chemical reduction, Optimized using PVP, Sodium borohydride and silver nitrate concentration. Particle size, Polydispersity index (PDI), Zeta potential(ZP), UV, FTIR, TEM, SEM, Drug release and kinetics studies were performed.
Results: Particle size found to be between 20.64 ±0.91 nm and 176.51±0.24 nm, PDI (0.283 ± 0.87 and 0.608 ± 0.06), and zetapotential (-13.0±0.89mV to – 10.5± 0.02mV). Drug release depicts a burst release pattern, succeeded by sustained release. Characterization studies also gave favourable results.
Conclusion: Optimized R-AgNPs showed improved stability, bioavailability and controlled release. Henceforth nanoparticle delivery systems should be further refined to optimize therapeutic efficacy.